LENZ Therapeutics Inc
LENZ
Company Profile
Business description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Contact
201 Lomas Santa Fe Drive
Suite 300
Solana BeachCA92075
USAT: +1 858 925-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
152
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.00 | 48.10 | 0.55% |
| CAC 40 | 8,174.01 | 29.42 | -0.36% |
| DAX 40 | 24,246.66 | 186.40 | -0.76% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,187.29 | 40.04 | -0.39% |
| HKSE | 24,407.96 | 157.94 | -0.64% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 64,179.27 | 1,237.36 | -1.89% |
| NZX 50 Index | 13,253.65 | 49.57 | 0.38% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,653.30 | 61.90 | 0.72% |
| SSE Composite Index | 3,993.23 | 16.80 | -0.42% |